Development and validation of a novel stem cell subtype for bladder cancer based on stem genomic profiling.
Source check: Source checked. Not independent scientific confirmation.
Finding: Supervised/unsupervised ML on six genomic datasets and 26 stem-cell gene sets yielded three bladder-cancer stem-enrichment subtypes, with cross-platform stability and distinct prognosis/immune/therapy associations. Predicted treatment sensitivities remain computational, not clinical response evidence. Organization is unavailable in the deposited bibliographic metadata.
Technology: Supervised and unsupervised machine-learning subtype models
Publication: Publication status unspecified in annotation · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Supervised/unsupervised ML on six genomic datasets and 26 stem-cell gene sets yielded three bladder-cancer stem-enrichment subtypes, with cross-platform stability and distinct prognosis/immune/therapy associations. Predicted treatment sensitivities remain computational, not clinical response evidence.
- Test and result
- Supervised/unsupervised ML on six genomic datasets and 26 stem-cell gene sets yielded three bladder-cancer stem-enrichment subtypes, with cross-platform stability and distinct prognosis/immune/therapy associations. Predicted treatment sensitivities remain computational, not clinical response evidence.
- Limitation / still unknown
- Predicted treatment sensitivities remain computational, not clinical response evidence.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC7594303/
The legacy label “Not reported” does not distinguish information absent from reviewed material from information not assessed. It is not a scientific finding of absence.
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.